在琼脂中对亚抑菌浓度的诺氟沙星产生耐药性增加的微生物的快速筛选。
Rapid selection of organisms with increasing resistance on subinhibitory concentrations of norfloxacin in agar.
作者信息
Tenney J H, Maack R W, Chippendale G R
出版信息
Antimicrob Agents Chemother. 1983 Jan;23(1):188-9. doi: 10.1128/AAC.23.1.188.
Abstract
Serial passage of Pseudomonas aeruginosa ATCC 27853 or Escherichia coli ATCC 25922 on agar with subinhibitory concentrations of norfloxacin rapidly produced isolates with minimal inhibitory concentrations (MICs) of norfloxacin up to 512-fold higher than that for the original strain. Although MICs of seven unrelated antibiotics were unchanged, increasing MICs occurred in parallel with norfloxacin, cinoxacin, and nalidixic acid regardless of which of these three organic acids was used to select for increased resistance. P. aeruginosa with a norfloxacin MIC of greater than 256 micrograms/ml could be selected; however, E. coli with MICs greater than the clinically achievable level of 16 micrograms/ml could not be produced.
摘要
在含有亚抑菌浓度诺氟沙星的琼脂上对铜绿假单胞菌ATCC 27853或大肠埃希菌ATCC 25922进行连续传代，很快就产生了对诺氟沙星的最低抑菌浓度（MIC）比原始菌株高512倍的分离株。尽管七种不相关抗生素的MIC没有变化，但无论使用这三种有机酸中的哪一种来选择增加耐药性，对诺氟沙星、西诺沙星和萘啶酸的MIC增加都是并行发生的。可以选择诺氟沙星MIC大于256微克/毫升的铜绿假单胞菌；然而，无法产生MIC大于临床可达到水平16微克/毫升的大肠埃希菌。
相似文献
1
Rapid selection of organisms with increasing resistance on subinhibitory concentrations of norfloxacin in agar.
Antimicrob Agents Chemother. 1983 Jan;23(1):188-9. doi: 10.1128/AAC.23.1.188.
2
In vitro comparison of norfloxacin with nalidixic acid, cinoxacin and oxolinic acid.
Arzneimittelforschung. 1983;33(12):1623-7.
3
Antibacterial activity of norfloxacin.
Antimicrob Agents Chemother. 1983 Jan;23(1):15-8. doi: 10.1128/AAC.23.1.15.
4
Cross-resistance among cinoxacin, ciprofloxacin, DJ-6783, enoxacin, nalidixic acid, norfloxacin, and oxolinic acid after in vitro selection of resistant populations.
Antimicrob Agents Chemother. 1984 Jun;25(6):775-7. doi: 10.1128/AAC.25.6.775.
5
In vitro emergence of Escherichia coli and Pseudomonas aeruginosa strains resistant to norfloxacin and nalidixic acid.
Eur J Clin Microbiol. 1983 Dec;2(6):600-1. doi: 10.1007/BF02016577.
6
Comparative activities of norfloxacin and fifteen other antipseudomonal agents against gentamicin-susceptible and -resistant Pseudomonas aeruginosa strains.
Antimicrob Agents Chemother. 1983 Oct;24(4):602-4. doi: 10.1128/AAC.24.4.602.
7
In vitro antibacterial activity of norfloxacin (MK-0366).
Antimicrob Agents Chemother. 1982 Apr;21(4):604-7. doi: 10.1128/AAC.21.4.604.
8
Norfloxacin: in vitro activity compared with that of seven other antibacterial agents against urinary tract pathogens.
Acta Pathol Microbiol Immunol Scand B. 1984 Apr;92(2):101-6. doi: 10.1111/j.1699-0463.1984.tb02802.x.
9
In vitro activity of MK-0366 against clinical urinary pathogens including gentamicin-resistant Pseudomonas aeruginosa.
Antimicrob Agents Chemother. 1982 Apr;21(4):670-2. doi: 10.1128/AAC.21.4.670.
10
In vitro activity of norfloxacin in synthetic media and human urine compared to that of cinnoxacin, nalidixic acid and pipemidic acid.
Methods Find Exp Clin Pharmacol. 1983 Dec;5(10):731-4.
引用本文的文献
1
Treatment failure due to emergence of resistance to carbapenem during therapy for Shewanella algae bacteremia.
J Clin Microbiol. 2006 Mar;44(3):1172-4. doi: 10.1128/JCM.44.3.1172-1174.2006.
2
Mutations of the Helicobacter pylori genes rdxA and pbp1 cause resistance against metronidazole and amoxicillin.
Antimicrob Agents Chemother. 2001 Mar;45(3):962-5. doi: 10.1128/AAC.45.3.962-965.2001.
3
Ineffectiveness of topoisomerase mutations in mediating clinically significant fluoroquinolone resistance in Escherichia coli in the absence of the AcrAB efflux pump.
Antimicrob Agents Chemother. 2000 Jan;44(1):10-3. doi: 10.1128/AAC.44.1.10-13.2000.
4
Characterization of fluoroquinolone-resistant mutants of escherichia coli selected in vitro.
Antimicrob Agents Chemother. 1994 Jun;38(6):1284-91. doi: 10.1128/AAC.38.6.1284.
5
In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent.
Antimicrob Agents Chemother. 1984 Mar;25(3):331-5. doi: 10.1128/AAC.25.3.331.
6
Cross-resistance among cinoxacin, ciprofloxacin, DJ-6783, enoxacin, nalidixic acid, norfloxacin, and oxolinic acid after in vitro selection of resistant populations.
Antimicrob Agents Chemother. 1984 Jun;25(6):775-7. doi: 10.1128/AAC.25.6.775.
7
Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria.
Antimicrob Agents Chemother. 1984 Mar;25(3):319-26. doi: 10.1128/AAC.25.3.319.
8
In vitro activity of enoxacin, a quinolone carboxylic acid, compared with those of norfloxacin, new beta-lactams, aminoglycosides, and trimethoprim.
Antimicrob Agents Chemother. 1983 Nov;24(5):754-63. doi: 10.1128/AAC.24.5.754.
9
Selection of multiple antibiotic resistance by quinolones, beta-lactams, and aminoglycosides with special reference to cross-resistance between unrelated drug classes.
Antimicrob Agents Chemother. 1984 Dec;26(6):797-801. doi: 10.1128/AAC.26.6.797.
10
The place of quinolones in antibacterial therapy in hospitals.
Pharm Weekbl Sci. 1986 Feb 21;8(1):72-8. doi: 10.1007/BF01975485.
本文引用的文献
1
In vitro activity of norfloxacin, a quinolinecarboxylic acid, compared with that of beta-lactams, aminoglycosides, and trimethoprim.
Antimicrob Agents Chemother. 1982 Jul;22(1):23-7. doi: 10.1128/AAC.22.1.23.
2
A critical evaluation of nalidixic acid in urinary-tract infections.
N Engl J Med. 1966 Nov 17;275(20):1081-9. doi: 10.1056/NEJM196611172752001.
3
Cinoxacin: in vitro antibacterial studies of a new synthetic organic acid.
Antimicrob Agents Chemother. 1975 Feb;7(2):159-63. doi: 10.1128/AAC.7.2.159.
4
The responses of Escherichia coli to nalidixic acid.
Chemotherapy. 1978;24(4):249-58. doi: 10.1159/000237789.
5
Nalidixic acid resistance: a second genetic character involved in DNA gyrase activity.
Proc Natl Acad Sci U S A. 1977 Nov;74(11):4772-6. doi: 10.1073/pnas.74.11.4772.
Zotero 插件